EP4118210A4 - Treatment of covid-19 and methods therefor - Google Patents

Treatment of covid-19 and methods therefor

Info

Publication number
EP4118210A4
EP4118210A4 EP21768699.7A EP21768699A EP4118210A4 EP 4118210 A4 EP4118210 A4 EP 4118210A4 EP 21768699 A EP21768699 A EP 21768699A EP 4118210 A4 EP4118210 A4 EP 4118210A4
Authority
EP
European Patent Office
Prior art keywords
covid
treatment
methods therefor
therefor
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP21768699.7A
Other languages
German (de)
French (fr)
Other versions
EP4118210A1 (en
Inventor
Patrick Soon-Shiong
Peter Sieling
Annie Shin
Leonard Sender
Jeffrey Safrit
Adrian Rice
Shahrooz Rabizadeh
Kayvan Niazi
Lise Geissert
Elizabeth Gabitzsch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunitybio Inc
Original Assignee
NantCell Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/883,263 external-priority patent/US11684668B2/en
Application filed by NantCell Inc filed Critical NantCell Inc
Priority claimed from PCT/US2021/021737 external-priority patent/WO2021183665A1/en
Publication of EP4118210A1 publication Critical patent/EP4118210A1/en
Publication of EP4118210A4 publication Critical patent/EP4118210A4/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/06—Fusion polypeptide containing a localisation/targetting motif containing a lysosomal/endosomal localisation signal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20071—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
EP21768699.7A 2020-03-11 2021-03-10 Treatment of covid-19 and methods therefor Pending EP4118210A4 (en)

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US202062988328P 2020-03-11 2020-03-11
US202063009960P 2020-04-14 2020-04-14
US202063010010P 2020-04-14 2020-04-14
US16/883,263 US11684668B2 (en) 2020-03-11 2020-05-26 Replication-defective adenoviruses comprising nucleic acids encoding SARS-CoV-2 s glycoprotein and modified N protein comprising an endosomal targeting sequence
US202063059975P 2020-08-01 2020-08-01
US202063064157P 2020-08-11 2020-08-11
US202063117922P 2020-11-24 2020-11-24
US202063117460P 2020-11-24 2020-11-24
US202063117847P 2020-11-24 2020-11-24
US202063118697P 2020-11-26 2020-11-26
US202163135380P 2021-01-08 2021-01-08
PCT/US2021/021737 WO2021183665A1 (en) 2020-03-11 2021-03-10 Treatment of covid-19 and methods therefor

Publications (2)

Publication Number Publication Date
EP4118210A1 EP4118210A1 (en) 2023-01-18
EP4118210A4 true EP4118210A4 (en) 2024-04-17

Family

ID=84463771

Family Applications (1)

Application Number Title Priority Date Filing Date
EP21768699.7A Pending EP4118210A4 (en) 2020-03-11 2021-03-10 Treatment of covid-19 and methods therefor

Country Status (2)

Country Link
EP (1) EP4118210A4 (en)
CN (1) CN115552011A (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003066820A2 (en) * 2002-02-05 2003-08-14 The Regents Of The University Of California Nucleic acid molecules encoding cd1-derived endosomal targeting proteins and uses thereof
US20180244756A1 (en) * 2015-02-24 2018-08-30 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Middle east respiratory syndrome coronavirus immunogens, antibodies, and their use

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003066820A2 (en) * 2002-02-05 2003-08-14 The Regents Of The University Of California Nucleic acid molecules encoding cd1-derived endosomal targeting proteins and uses thereof
US20180244756A1 (en) * 2015-02-24 2018-08-30 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Middle east respiratory syndrome coronavirus immunogens, antibodies, and their use

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
ELIZABETH S GABITZSCH ET AL: "Anti-tumor immunotherapy despite immunity to adenovirus using a novel adenoviral vector Ad5 [E1-, E2b-]-CEA", CANCER IMMUNOLOGY, IMMUNOTHERAPY, SPRINGER, BERLIN, DE, vol. 59, no. 7, 2 April 2010 (2010-04-02), pages 1131 - 1135, XP019800230, ISSN: 1432-0851 *
ENJUANES ET AL: "Vaccines to prevent severe acute respiratory syndrome coronavirus-induced disease", VIRUS RESEARCH, AMSTERDAM, NL, vol. 133, no. 1, 11 March 2008 (2008-03-11), pages 45 - 62, XP022520312, ISSN: 0168-1702, DOI: 10.1016/J.VIRUSRES.2007.01.021 *
RAYMOND H SEE ET AL: "Comparative evaluation of two severe acute respiratory syndrome (SARS) vaccine candidates in mice challenged with SARS coronavirus", JOURNAL OF GENERAL VIROLOGY, SOCIETY FOR GENERAL MICROBIOLOGY, vol. 87, no. 3, 1 March 2006 (2006-03-01), pages 641 - 650, XP008138952, ISSN: 0022-1317, DOI: 10.1099/VIR.0.81579-0 *
RICE ADRIAN ET AL: "A Next Generation Bivalent Human Ad5 COVID-19 Vaccine Delivering Both Spike and Nucleocapsid Antigens Elicits Th1 Dominant CD4+, CD8+ T-cell and Neutralizing Antibody Responses", BIORXIV, 30 July 2020 (2020-07-30), pages 1 - 36, XP055929959, DOI: 10.1101/2020.07.29.227595 *
See also references of WO2021183665A1 *
SHI JIANDONG ET AL: "Epitope-Based Vaccine Target Screening against Highly Pathogenic MERS-CoV: An In Silico Approach Applied to Emerging Infectious Diseases", PLOS ONE, vol. 10, no. 12, 7 December 2015 (2015-12-07), US, pages e0144475, XP093130066, ISSN: 1932-6203, DOI: 10.1371/journal.pone.0144475 *
SIELING PETER ET AL: "Th1 Dominant Nucleocapsid and Spike Antigen-Specific CD4+ and CD8+ Memory T Cell Recall Induced by hAd5 S-Fusion + N-ETSD Infection of Autologous Dendritic Cells from Patients Previously Infected with SARS-CoV-2", MEDRXIV, 6 November 2020 (2020-11-06), pages 1 - 44, XP055845509, Retrieved from the Internet <URL:https://www.medrxiv.org/content/10.1101/2020.11.04.20225417v1.full.pdf> [retrieved on 20210928], DOI: 10.1101/2020.11.04.20225417 *

Also Published As

Publication number Publication date
CN115552011A (en) 2022-12-30
EP4118210A1 (en) 2023-01-18

Similar Documents

Publication Publication Date Title
IL288061A (en) Compounds and methods for the treatment of covid-19
EP3920923A4 (en) Therapeutic agents and methods of treatment
EP4090658A4 (en) Therapeutic agents and methods of treatment
EP4110369A4 (en) Methods of treatment and related compositions
GB2604264B (en) Medical treatment device and method of operation thereof
GB202314118D0 (en) Methods of classifying and treating patients
GB202317431D0 (en) Arrangement and method for treatment of fish
EP4118210A4 (en) Treatment of covid-19 and methods therefor
GB202217355D0 (en) Methods for the prophylaxis and treatment of Covid and Covid-19
EP4017493A4 (en) Methods of treatment using bcn057 and bcn512
GB202118007D0 (en) Methods of treatment
GB202118011D0 (en) Methods of treatment
GB202118006D0 (en) Methods of treatment
GB202108245D0 (en) Methods of treatment
GB202108242D0 (en) Methods of treatment
GB202005874D0 (en) Methods of treatment
GB202107966D0 (en) Composition and method of treatment
GB202201819D0 (en) Methods of treatment
GB202201824D0 (en) Methods of treatment
GB202201825D0 (en) Methods of treatment
GB202119051D0 (en) Wingsail and method of use
GB202000248D0 (en) Compositions and methods of treatment
GB202317378D0 (en) Composition and methods of treatment
GB202213287D0 (en) Methods of diagnosis and treatment
GB202207570D0 (en) Methods of treatment and diagnosis

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20220914

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: NANTCELL, INC.

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: C12N0015620000

Ipc: A61K0035761000

A4 Supplementary search report drawn up and despatched

Effective date: 20240318

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 39/12 20060101ALI20240312BHEP

Ipc: C12N 15/81 20060101ALI20240312BHEP

Ipc: A61P 31/14 20060101ALI20240312BHEP

Ipc: C07K 14/005 20060101ALI20240312BHEP

Ipc: A61K 39/215 20060101ALI20240312BHEP

Ipc: C12N 15/86 20060101ALI20240312BHEP

Ipc: A61K 35/761 20150101AFI20240312BHEP